Exhibit 99.1
Ciphergen Reports Second Quarter 2003 Financial Results
Revenue Increased 65% vs. Year Prior Period
FREMONT, Calif., July 24 /PRNewswire-FirstCall/ -- Ciphergen Biosystems,
Inc. (Nasdaq: CIPH) reported financial results for the second quarter of 2003.
For the quarter ended June 30, 2003, total revenue increased 65% to
$14.3 million, up from revenue of $8.7 million in the second quarter of 2002.
The increase in revenue was due to increased sales of ProteinChip(R) Systems
and Arrays, increased sales of automation accessories, increased revenue from
Ciphergen's BioSepra(R) Process Proteomics products, and increased revenue
from service activities. Due to the litigation settlement achieved in the
second quarter, Ciphergen recorded $7.3 million as a non-recurring expense
which was recorded in cost of revenue. The Company reported a net loss of
$15.6 million for the second quarter of 2003, compared to a net loss of
$7.3 million for the comparable period of 2002.
"We are pleased to report another strong quarter for Ciphergen, as our
systems, consumables and services revenue continued to grow at a rapid rate.
We continue to expand our business on all fronts including broadening our
customer base, developing and launching innovative new products and
strengthening our patent estate," commented William Rich, President and CEO of
Ciphergen. "With the litigation behind us, and uncontested freedom to fully
exploit the SELDI technology, we are expanding our business initiatives to
other potentially lucrative markets including the discovery and development of
protein-based clinical diagnostics and theranostics."
Financial Impact of Litigation Settlement. Under the terms of the
settlement, Ciphergen paid to LumiCyte $3 million in cash and issued
1.25 million shares of Ciphergen stock. In addition, Ciphergen will pay
royalties of up to $10 million over a 10-year period to Molecular Analytical
Systems. To account for these obligations, Ciphergen recorded during this
quarter approximately $7.3 million in a non-recurring expense in cost of
revenue. Ciphergen anticipates recording approximately $1.2 million per year
in additional cost of revenue over the next 11 years with respect to this
settlement.
The following is a reconciliation of selected financial information
prepared according to Generally Accepted Accounting Principles (GAAP) with
selected non-GAAP financial information. Management believes that this
adjustment for non-recurring expense associated with the litigation settlement
enhances an investor's ability to compare the Company's results of operations
for the three and six month periods ended June 30, 2003 to its results for
historic and future quarterly periods. Management relies on this presentation
internally for purposes of comparing such periods.
Selected Financial Information
(Unaudited)
(in thousands)
Three Months Ended Six Months Ended
June 30, June 30,
GAAP presentation 2002 2003 2002 2003
Revenue $8,653 $14,264 $15,467 $27,105
Cost of revenue 2,848 11,962 5,350 16,785
Gross profit 5,805 2,302 10,117 10,320
Net loss (7,297) (15,605) (14,460) (24,801)
Adjustment for non-recurring
expense associated with
litigation settlement
Cost of revenue $-- $(7,257) $-- $(7,257)
Pro forma selected financials
Revenue $8,653 $14,264 $15,467 $27,105
Cost of revenue 2,848 4,705 5,350 9,528
Gross profit 5,805 9,559 10,117 17,577
Net loss (7,297) (8,348) (14,460) (17,544)
Revenue Guidance. Although revenue continued to grow rapidly during the
second quarter, Ciphergen's revenue reflected for the first time a softer
purchasing environment in the U.S. We expect improving business conditions in
the second half of 2003 in the U.S. and the Company continues to expect that
2003 revenue will be in the range of our original revenue guidance of
$65-70 million.
Summary Highlights for the Quarter:
Litigation Settlement. Ciphergen cemented its rights to its core SELDI
technology through a settlement with LumiCyte and Molecular Analytical Systems
that provides Ciphergen with an exclusive worldwide license and the right to
sublicense the technology and to commercialize any and all products,
information and services derived from the technology without limitation.
Expanding Biomarker Discovery and Diagnostic Commercialization in Cancer
Research.
-- 48 AACR Abstracts. 48 scientific clinical proteomics studies
highlighting the use of Ciphergen's SELDI ProteinChip platform in
cancer research were published in the proceedings of the American
Association for Cancer Research's 2003 Meeting, nearly doubling the
number of citations at last year's meeting. Many of the publications
document new and exciting progress in early cancer detection,
mechanisms of drug resistance, and correlation of genomic and
proteomic data.
-- Colon Cancer Collaboration with bioMerieux. Ciphergen also
established a diagnostic biomarker discovery collaboration with
bioMerieux S.A. by which the two companies will work together to
discover biomarkers and multi-biomarker panels that may improve the
diagnosis and management of colon cancer using Ciphergen's
ProteinChip technology.
-- ProteinChip Diagnostics Discovery and Commercialization Rights
Licensed to Leading Canadian Clinical Research Group. Toronto
Medical Laboratories (TML) has acquired Ciphergen's AutoBiomarker
ProteinChip System along with discovery and commercialization
licenses, with an objective of pursuing targeted assay development
projects aimed at identifying new protein biomarkers that can be
converted into commercial diagnostic tests in cancer and organ
transplantation. Projects include TML and the McLaughlin Centre
using the ProteinChip technology to conduct biomarker discovery and
clinical studies on large organ transplant rejection markers, the
early diagnosis of endometrial, thyroid and lung cancer, and the
identification of predictors of response to novel therapeutic agents
in colon cancer, leukemia and myeloma.
Progress in SARS Research. Ciphergen's ProteinChip technology is being
employed by multiple groups, including Health Canada's National Microbiology
Lab, Beijing Clinical SARS Testing Center and the Genomic Institute of
Singapore, in the hunt for novel protein biomarkers associated with Severe
Acute Respiratory Syndrome (SARS). A number of potential biomarkers have
already been discovered in SARS patient samples; these proteins are being
identified and will be further evaluated for their utility in developing
accurate diagnostic tests for SARS. If successful, therapeutic and/or vaccine
strategies based on insights provided from these biomarkers may be pursued as
well.
New Product Introductions. During the quarter, Ciphergen launched its
new Interaction Discovery Mapping(TM) (IDM) platform, representing a further
development in Clinical Proteomics application tools that enables rapid
protein interaction studies and complements our proven Expression Difference
Mapping(TM) (EDM) capability for biomarker discovery and provides improved
capabilities in functional proteomics applications. The IDM platform enables:
-- Rapid discovery of new protein interaction-related biomarkers;
-- Elucidation of disease-associated biological pathways and function,
as well as novel therapeutic strategies; and
-- Development of rapid, quantitative multi-marker assays for disease
diagnosis, prognosis and treatment monitoring as well as improved
clinical sensitivity and specificity.
In addition, Ciphergen launched the first of a family of "matrix-free"
ProteinChip Arrays which enable low molecular weight species to be detected
with greatly improved signal-to-noise. In comparative studies between our
SEND technology and traditional MALDI, protein digests are routinely detected
at around 10x better sensitivity and with up to 90% sequence coverage.
Expanding Process Proteomics. Ciphergen opened its newest Process
Proteomics Center located near Boston, MA. Leveraging the company's
ProteinChip System and high performance BioSepra protein purification
technologies, the center is dedicated to providing rapid and effective
solutions to difficult protein production issues in the realm of
biopharmaceutical product development and production. The opening of this
center strengthens the Company's ability to provide advanced protein
expression and purification solutions to its biopharmaceutical and
biotechnology clients. Ciphergen is pioneering the field of Process
Proteomics whereby ProteinChip and BioSepra technologies are combined to
dramatically simplify and accelerate the development and production of
proteins at all scales. The new center's services will include novel
approaches to research and large-scale protein expression optimization,
chromatography purification development, analytical methods development and
biomanufacturing process development.
Key Patents Issued. Two key patents were issued during the quarter
directed to Ciphergen's core technologies -- European Patent Number
EP 0 700 521 B1, directed to Surface-Enhanced Laser Desorption Ionization
(SELDI) technology; and United States Patent 6,579,719, directed to protein
expression profiling using SELDI. The European patent secures our rights to
our core SELDI technology in Europe, and the U.S. patent supplements our basic
U.S. patents with coverage for the most important ProteinChip technology
application -- protein expression profiling -- which is at the heart of
protein biomarker discovery.
About Ciphergen
Ciphergen develops, manufactures and markets a family of ProteinChip(R)
Systems and services for clinical, research and process proteomics
applications, as well as a broad range of bioseparations media for protein
purification through its BioSepra(R) process chromatography division.
ProteinChip Systems and Biomarker Discovery Center(R) collaborative services
enable protein discovery, profiling, characterization and assay development to
provide researchers with predictive analysis capabilities and a better
understanding of biological functions at the protein level. ProteinChip
Systems are enabling tools in the emerging field of protein-based biology
research, known as proteomics. Proteomics provides a direct approach to
understanding the role of proteins in the biology of disease, monitoring
disease progression and evaluating the therapeutic effects and side effects of
drugs. Ciphergen believes proteomics will be a major focus of biological
research by enhancing the understanding of gene function and the molecular
basis of disease. Additional information about Ciphergen can be found at
www.ciphergen.com.
Safe Harbor Statement
Note Regarding Forward-Looking Statements: This press release contains
forward-looking statements, including statements regarding the use of
ProteinChip technology to discover useful protein biomarkers that can be used
for diagnostic, theranostic and/or drug development purposes, future
additional cost of revenue arising from our litigation settlement, the
Company's revenue projections for 2003, the development of diagnostic tests
for various cancers including colon cancer as well as for SARS, potential
therapeutics or vaccines that might arise from SARS biomarker discovery
efforts, the successful applications of our IDM platform, our ability to
combine ProteinChip and BioSepra technologies to simplify and accelerate the
development and production of proteins at all scales, and future growth in the
field of proteomics. Actual results may differ materially from those
projected in such forward-looking statements due to various factors, including
the ProteinChip technology's ability to discover protein biomarkers that have
diagnostic, theranostic and/or drug development utility, the possibility that
the impact of the litigation settlement on cost of revenue in future years
could be greater than that stated due to an impairment of the useful life of
the SELDI technology, the Company's ability to generate significant growth in
unit sales while maintaining pricing, the IDM platform's ability to rapidly
discover protein interactors, elucidate disease pathways and functions, and to
develop useful assays, and the continued emergence of proteomics as a major
focus of biological research and drug discovery. Investors should consult
Ciphergen's filings with the Securities and Exchange Commission, including its
Form 10-K for the year ended December 31, 2002 and pending Registration
Statement on Form S-3 filed on June 24, 2003, for further information
regarding these and other risks of the Company's business.
NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center and BioSepra are
registered trademarks of Ciphergen Biosystems, Inc.
Ciphergen Biosystems, Inc.
Summary Financial Information
(Unaudited)
(in thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
2002 2003 2002 2003
Revenue $8,653 $14,264 $15,467 $27,105
Cost of revenue (A) 2,848 11,962 5,350 16,785
Gross profit 5,805 2,302 10,117 10,320
Operating expenses:
Research and development 4,701 7,011 8,621 13,392
Sales and marketing 5,148 6,097 9,928 11,946
General and administrative 3,337 4,246 6,304 8,954
Amortization
of intangible assets 207 207 414 414
Total operating expenses 13,393 17,561 25,267 34,706
Loss from operations (7,588) (15,259) (15,150) (24,386)
Interest and other income, net 383 (44) 799 288
Loss before income taxes (7,205) (15,303) (14,351) (24,098)
Income tax provision 92 302 109 703
Net loss $(7,297) $(15,605) $(14,460) $(24,801)
Net loss per share,
basic and diluted $(0.27) $(0.56) $(0.54) $(0.90)
Shares used in computing
net loss per share 26,898 27,782 26,846 27,498
December 31, June 30,
2002 2003
Cash, cash equivalents
and investments in securities $42,541 $28,231
Total assets 87,615 76,949
Stockholders' equity 68,354 53,781
(A) In the three months and six months ended June 30, 2003 cost of
revenue included a non-recurring $7,257 expense related to our
litigation settlement.
SOURCE Ciphergen Biosystems, Inc.
-0- 07/24/2003
/CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems,
Inc., +1-510-505 2297/
/Web site: http://www.ciphergen.com/
(CIPH)
CO: Ciphergen Biosystems, Inc.
ST: California
IN: HEA OFP
SU: ERN